Related Experiment Video
Updated: May 19, 2026

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
Published on: January 7, 2019
Overview of the cancer vaccine field: are we moving forward?
1Pharmaceutical Medicine, London, UK. koudrine@hotmail.com
Abstract:
Cancer immunotherapy has seen a tremendous number of failures and only few recent regulatory successes. This review is a first in a series dedicated to evaluate the status of current global clinical pipeline for cancer vaccines. Apart from specific areas of medical need which can be addressed by cancer vaccines, the analysis of the pipeline by clinical indication suggests that a disproportionately large number of candidates is currently developed in prostate, breast, lung cancer and melanoma with significant gap of candidates in remaining oncology indications. With potential offering and benefits that cancer immunotherapy could bring to patient community and society as a whole, we require new innovative R&D, improved Antigen Discovery programs and business models to fill serious gaps in cancer vaccine R&D pipeline.
Insights
Cancer vaccines show promise but face many R&D gaps. This review analyzes the global pipeline, finding many candidates for common cancers but few for others, highlighting the need for innovation.
Area of Science:
- Oncology
- Immunology
- Vaccinology
Background:
- Cancer immunotherapy has experienced numerous failures, with limited recent regulatory approvals.
- Cancer vaccines represent a critical area of therapeutic development with significant potential benefits.
Purpose of the Study:
- To evaluate the current global clinical pipeline for cancer vaccines.
- To identify gaps and areas for improvement in cancer vaccine research and development.
Main Methods:
- Systematic review of the global clinical pipeline for cancer vaccines.
- Analysis of vaccine candidates by clinical indication.
Main Results:
- The cancer vaccine pipeline shows a disproportionate concentration of candidates in prostate, breast, and lung cancers, and melanoma.
- A significant gap exists in the development of cancer vaccine candidates for other oncology indications.
- Few recent regulatory successes highlight challenges in the field.
Conclusions:
- Innovative research and development are crucial to address the identified gaps in the cancer vaccine pipeline.
- Improved antigen discovery programs and business models are necessary to advance cancer vaccine development.
- Addressing the R&D pipeline gaps is essential to realize the full potential of cancer immunotherapy.
More Related Videos
10:18Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction
Published on: July 7, 2023
07:33Preparation, Characteristics, Toxicity, and Efficacy Evaluation of the Nasal Self-Assembled Nanoemulsion Tumor Vaccine In Vitro and In Vivo
Published on: September 28, 2022
Related Concept Videos
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Tumor Immunotherapy
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Cancer Prevention
Some...
Cancer Prevention
Some...